NRX Pharmaceuticals, Inc. (NRXP) - Form 8-K Summary
Business Context and Reporting Period
NRX Pharmaceuticals, Inc. filed this Current Report on Form 8-K on February 17, 2026. The filing relates to the Company's capital markets activities under an existing At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The only financial figure disclosed is the aggregate value of shares authorized for sale under the prospectus supplement: $20,000,000.
Material Changes
The Company filed a prospectus supplement on February 17, 2026, to authorize the sale of up to $20,000,000 of its common stock under the ATM Offering Agreement dated August 14, 2023. These shares are issuable under the registration statement on Form S-3 (File No. 333-288205), which was declared effective on December 22, 2025.
Guidance, Outlook, and Risks
The filing includes a legal opinion from Cozen O'Connor regarding the validity of the shares to be issued, filed as Exhibit 5.1. No management commentary, forward-looking guidance, or specific risk factors were disclosed in this document beyond the standard legal opinion requirement.
Investor Verification Checklist
- Verify the effective date of the underlying Form S-3 registration statement (December 22, 2025).
- Review the full text of the legal opinion from Cozen O'Connor (Exhibit 5.1) regarding share validity.
- Monitor subsequent filings for actual share sales and proceeds generated under the $20,000,000 ATM authorization.
- Check the Company's latest 10-K or 10-Q for current liquidity and cash position, as this 8-K does not provide those figures.